Gensight Biologics S.a annual working capital
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Working Capital Growth & History (SIGHT)
Gensight Biologics S.a's working capital was −€7.7M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€7.7M | €9.6M | — |
| 2024 | 2024-12-31 | −€17.3M | €1.5M | — |
| 2023 | 2023-12-31 | −€18.8M | −€27.1M | — |
| 2022 | 2022-12-31 | €8.3M | −€22.8M | −73.31% |
| 2021 | 2021-12-31 | €31.1M | €4.5M | +16.84% |
| 2020 | 2020-12-31 | €26.6M | — | — |
Gensight Biologics S.a quarterly working capital
Q4.24
Q4.25
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −€7.7M | €9.6M | — |
| Q4 2024 | 2024-12-31 | −€17.3M | — | — |
Gensight Biologics S.a working capital trends
Over the last five fiscal years, Gensight Biologics S.a's working capital decreased from €26.6M to −€7.7M, a change of −€34.3M. The latest reported quarter, Q4 2025, shows −€7.7M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...